Clinical trials
Biliary Tract Cancer clinical trials
Below are recruiting biliary tract cancer clinical trials, each written for real people, not researchers. We’re tracking 137 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07606599RecruitingPhase 3
New drug BL-M07D1 for advanced biliary tract cancer
This trial tests a new drug called BL-M07D1 against standard chemotherapy for biliary tract cancer that has spread or is locally advanced and has stopped responding to platinum-based chemotherapy. The trial is looking for patients whose cancer has a specific genetic marker to see if this new treatment works better.
Hefei, AnhuiAges 18–75 - NCT07582315RecruitingPhase 3
BL-B01D1 for advanced biliary tract cancer after prior treatments
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Beijing, Beijing MunicipalityAges 18–75 - NCT07569679RecruitingPhase 2
Combination Chemotherapy and Immunotherapy for Biliary Tract Cancer
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
Xi'an, ShaanxiAges 18 years+ - NCT06749730RecruitingPhase 2
Study of four drugs for advanced bile duct cancer
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
ZhengzhouAges 18–80 - NCT06653127Recruiting
Using a blood test to watch for biliary tract cancer return
This trial studies a new blood test that looks for bits of tumor DNA (ct-mtDNA) to see if it can detect if biliary tract cancer has come back earlier than standard scans. The test might help doctors monitor for recurrence more closely.
Wuhan, HubeiAges 18 years+ - NCT07530445RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced biliary tract cancer
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted drug (lenvatinib) for biliary tract cancer that has spread or cannot be surgically removed. The goal is to slow cancer growth in patients whose cancer has progressed after one prior treatment.
GuangzhouAges 18–70 - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT07466238Recruiting
Chemo into the liver plus IV chemo for bile duct cancer
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
BeijingAges 18–80 - NCT05222971RecruitingPhase 2
Olaparib, with or without immunotherapy, for DNA-repair biliary cancer
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
SeoulAges 19 years+ - NCT07450976RecruitingPhase 2
Targeted drug for advanced biliary tract cancer after standard treatment
This trial tests a new targeted drug (SHR-A1904) in people with advanced biliary tract cancer whose tumors have a specific protein (Claudin18.2) and who have already tried at least one standard treatment. The goal is to see if this drug can shrink the cancer or slow its growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT05749900RecruitingPhase 1/Phase 2
First-line antibody, chemo, and immunotherapy for HER2 bile duct cancer
This trial studies a combination of trastuzumab (an antibody), gemcitabine and cisplatin (chemo), plus nivolumab (immunotherapy) as the first treatment for advanced HER2-positive biliary tract cancer. It may help shrink tumors and improve outcomes by targeting HER2 and boosting the immune system.
SeoulAges 19 years+ - NCT06139042Recruiting
Early detection of liver, bile duct, and pancreas cancers
This study aims to find new ways to detect liver, bile duct, and pancreatic cancers early using a blood test. It may help doctors diagnose these cancers sooner, when they are easier to treat.
Hangzhou, ZhejiangAges 40–75 - NCT07392541RecruitingPhase 1/Phase 2
Study of adebrelimab plus chemo and simvastatin for bile duct cancer
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy (gemcitabine and cisplatin), and a cholesterol-lowering drug (simvastatin) for advanced bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if the addition of simvastatin improves treatment outcomes.
Wuhan, HubeiAges 18 years+ - NCT06778031RecruitingPhase 2
Study of SHR-A1811 for HER2-positive bile duct cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Harbin, HeilongjiangAges 18–75 - NCT07326137Recruiting
Pain relief and first-line treatment for advanced bile duct or pancreatic cancer
This study tests combining standard first-line cancer therapy with a nerve block to reduce pain in people with advanced bile duct or pancreatic cancer. It aims to see if this combination can improve pain control and quality of life.
Wuhan, HubeiAges Any age - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT07265674RecruitingPhase 3
Study of nanvuranlat for advanced bile duct cancer
This study tests a new drug called nanvuranlat for people with advanced bile duct cancer that has gotten worse after platinum-based chemotherapy. It compares nanvuranlat with the doctor's choice of standard treatments to see which works better.
Duarte, CaliforniaAges 18 years+ - NCT07267078RecruitingPhase 2
Tuvonralimab and Iparomlimab before surgery for bile duct cancer
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06620848RecruitingPhase 2
A trial of HRS-4642 alone or with adebrelimab for advanced bile duct cancer
This trial tests a new drug, HRS-4642, either by itself or combined with another drug called adebrelimab, for people whose advanced bile duct cancer has come back or gotten worse after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07229625RecruitingPhase 3
New drug combination for advanced bile duct cancer
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
Hangzhou, ZhejiangAges 18–75 - NCT07221253RecruitingPhase 3
Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Birmingham, AlabamaAges 18 years+ - NCT07206355Recruiting
Studying bile duct and liver lesions for new cancer tests
This study looks at tissue samples from people with bile duct, liver, or pancreas problems to develop better ways to detect cancers in these areas. If you are scheduled for a biopsy, scan, or surgery for a suspected growth in your liver, pancreas, or bile duct, you may be able to help.
NottinghamAges 16 years+ - NCT07176962Recruiting
Blood test for early detection of bile duct cancer
This study is testing a new blood test that looks for signs of DNA changes linked to biliary tract cancer. It aims to see if the test can find these cancers early. If you have biliary tract cancer or a high suspicion of it, you may be able to help.
Shanghai, Shanghai MunicipalityAges 18–80
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary tract cancer?
- Yes. Clin2 currently lists 137 recruiting biliary tract cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary tract cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary tract cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.